Want to see TSE:MSCL full AI Analyst Report?
MSCL Stock Chart & Stats
C$11.91
C$0.01(1.16%)
At close: 4:00 PM EST
C$11.91
C$0.01(1.16%)
Day’s Range― - ―
52-Week RangeC$6.36 - C$18.98
Previous CloseN/A
Volume29.01K
Average Volume (3M)178.54K
Market Cap
C$247.89M
Enterprise ValueC$48.81
Total Cash (Recent Filing)C$69.96M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 31, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding20,831,190
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$25.53Price Target Upside114.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially reduces solvency risk and fixed financing obligations, giving management flexibility to time dilutive financing or pursue partnership milestones. This durable strength extends runway options versus leveraged peers during multi-year clinical development.
Clinical-stage Focus On Regenerative Medicines For DMDTargeting DMD and muscle regeneration addresses a high unmet-need, orphan market where successful clinical data can create durable competitive positioning, regulatory incentives, and commercial exclusivity. Clinical milestones drive lasting value inflection and partnership/licensing optionality.
Lean, Focused R&D OrganizationA small, focused team can be more capital-efficient in early-stage development, lowering fixed overhead and stretching cash runway per dollar spent. This nimble operating model supports disciplined milestone-driven spending over the next several quarters of clinical work.
Bears Say
Persistent Negative Free Cash Flow (~-25.8M TTM)Sustained negative free cash flow indicates the company is consuming cash to fund operations rather than generating it. Over a multi-quarter horizon this necessitates external financing, raising dilution and execution risk if capital markets or partner deals are delayed or unfavourable.
Pre-revenue With Widening Operating And Net Losses (~28.5M TTM)Being pre-revenue with expanding losses means the company has no commercial cash flow to absorb R&D spend. Long-term viability depends on successful trials or recurring funding; failure or delays in development directly threaten sustainability and investor returns.
Volatile Equity And Prior Material Capital ActivitySharp swings in shareholders' equity point to past dilutive financings or write-downs and signal a likelihood of future capital raises to fund burn. This structural dilution risk can erode long-term shareholder value and ties the company's prospects to capital market access.
Satellos Bioscience News
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$6.36 and its highest was C$18.98 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is C$247.89M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 39 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 15, 2026. The company reported -C$0.729 earnings per share for the quarter, missing the consensus estimate of -C$0.675 by -C$0.054.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.73.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 20,831,190 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.729 in its last earnings report, missing expectations of -C$0.675. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$25.53 (114.40% Upside)
C$25.53 (114.40% Upside)
Blogger Sentiment
Bullish
TSE:MSCL Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth C$286.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
69.55%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
MSCL Stock 12 Month Forecast
Average Price Target
C$25.53
▲(114.40% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―